Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Platinum-resistant Ovarian Cancer (PROC)
Interventions
DRUG

Realgar-Indigo Naturalis Formulation Combined with Anlotinib

"RIF: Oral administration after meals, 6 tablets each time, three times daily (tid), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Anlotinib : Oral administration before breakfast, 10 mg each time, once daily (qd), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Subjects will continue the study treatment until meeting the protocol-defined discontinuation criteria. The total treatment duration should not exceed 18 months."

All Listed Sponsors
collaborator

Beijing Friendship Hospital

OTHER

collaborator

Peking University First Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Tianjin People's Hospital

OTHER

collaborator

The First Affiliated Hospital of Shanxi Medical University

OTHER

collaborator

Tianchang Yifan Pharmaceutical Co., Ltd.

UNKNOWN

lead

Peking University People's Hospital

OTHER